This spontaneous case was reported by a patient and describes the occurrence of ILLNESS (Within 24 hours of the 2nd dose she became sick with what she says are Covid), DYSPNOEA (She couldn't breathe, was out of breath just walking down the hall), ORAL DISORDER (mouth lesions/ she had lesions on her tongue, the roof of her mouth and down her throat), THROAT LESION (mouth and throat lesions/her throat was full, she had lesions on her tongue, the roof of her mouth and down her throat/ she had strep, for which they never tested her.) and ORAL CANDIDIASIS (had thrush on her tongue) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 020B21A and 036A21A) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below. Co-suspect product included non-company product TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for an unknown indication. No Medical History information was reported. On 04-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In September 2021, the patient received dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (unknown route) 1 dosage form. In April 2021, the patient experienced ILLNESS (Within 24 hours of the 2nd dose she became sick with what she says are Covid), DYSPNOEA (She couldn't breathe, was out of breath just walking down the hall) and FATIGUE (chronic fatigue). In July 2021, the patient experienced DYSPLASIA (was diagnosed with mono and dysplasia). On 04-May-2022, the patient experienced EPSTEIN-BARR VIRUS INFECTION (she had some specialized testing done and was diagnosed with Epstein Barr). On an unknown date, the patient experienced ORAL DISORDER (mouth lesions/ she had lesions on her tongue, the roof of her mouth and down her throat), THROAT LESION (mouth and throat lesions/her throat was full, she had lesions on her tongue, the roof of her mouth and down her throat/ she had strep, for which they never tested her.), ORAL CANDIDIASIS (had thrush on her tongue), DYSPHAGIA (she couldn't swallow), COUGH (had a horrible cough) and APHONIA (Lost her voice, which she just got back after speech therapy for 4 months.). In April 2021, ILLNESS (Within 24 hours of the 2nd dose she became sick with what she says are Covid) and DYSPNOEA (She couldn't breathe, was out of breath just walking down the hall) had resolved. At the time of the report, ORAL DISORDER (mouth lesions/ she had lesions on her tongue, the roof of her mouth and down her throat), THROAT LESION (mouth and throat lesions/her throat was full, she had lesions on her tongue, the roof of her mouth and down her throat/ she had strep, for which they never tested her.), DYSPHAGIA (she couldn't swallow) and FATIGUE (chronic fatigue) had not resolved, ORAL CANDIDIASIS (had thrush on her tongue), COUGH (had a horrible cough), DYSPLASIA (was diagnosed with mono and dysplasia) and EPSTEIN-BARR VIRUS INFECTION (she had some specialized testing done and was diagnosed with Epstein Barr) outcome was unknown and APHONIA (Lost her voice, which she just got back after speech therapy for 4 months.) had resolved. For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments. No concomitant medications were reported. Reporter reported that patient not had Covid that she knows of. It was reported that, the breathing and Covid symptoms lasted for 19 days. The lesions and fatigue continued. Patient eventually went to an urgent care who told her she had strep, for which they never tested her. She got her voice back after speech therapy for 4 months. She saw a dentist then eventually went to hospital and was diagnosed with mono and dysplasia. She had to take medications with pudding due to her continued swallowing issues. She got a Pfizer booster got sick again but only for a couple of days. She stated the lesions have only been gone for a couple of months. No treatment medications were reported.